Literature DB >> 15609331

c-myc-induced hepatocarcinogenesis in the absence of IGF-I receptor.

Axelle Cadoret1, Christèle Desbois-Mouthon, Dominique Wendum, Patricia Leneuve, Christine Perret, François Tronche, Chantal Housset, Martin Holzenberger.   

Abstract

Numerous tumours, including hepatocarcinomas, produce IGFs, and some depend on these growth factors in a paracrine or autocrine fashion. We have shown that c-myc-induced experimental hepatocarcinogenesis is associated with enhanced production of IGF-II. To assess the role of the IGF-I receptor (IGF-IR) in hepatocarcinogenesis, we generated conditional mutant mice that overexpressed c-myc and were knocked out for IGF-IR specifically in the liver. We compared these mice with littermate controls that also overexpressed c-myc but had wild-type IGF-IR alleles. We found that the pretumoral phase, induced by early c-myc expression and characterised by increased cell proliferation, was largely unaffected by the lack of IGF-IR. To our further surprise, hepatocellular carcinomas (HCCs) lacking IGF-IR readily developed and progressed at the same rate as control HCCs. At 9 months, all c-myc transgenic mice displayed well-differentiated multifocal tumours, regardless of whether their livers-and their tumours-were able to produce IGF-IR. Levels of IRS-1 and IRS-2 were elevated in all tumours in the presence or absence of IGF-IR, suggesting that the signalling pathway downstream of IGF-IR is activated via IGF-IR-independent mechanisms in HCC. In conclusion, the deregulation of IGF signalling pathways, which often occurs during liver tumorigenesis, does not necessarily require IGF-IRs, and hepatic IGF-IR alone may not play a determinant role in c-myc-induced hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609331     DOI: 10.1002/ijc.20805

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy.

Authors:  Jaetaek Kim; Adam R Wende; Sandra Sena; Heather A Theobald; Jamie Soto; Crystal Sloan; Benjamin E Wayment; Sheldon E Litwin; Martin Holzenberger; Derek LeRoith; E Dale Abel
Journal:  Mol Endocrinol       Date:  2008-09-18

2.  Differential organ phenotypes after postnatal Igf1r gene conditional deletion induced by tamoxifen in UBC-CreERT2; Igf1r fl/fl double transgenic mice.

Authors:  Icíar Paula López; Lourdes Rodriguez-de la Rosa; Rosete Sofia Pais; Sergio Piñeiro-Hermida; Raquel Torrens; Julio Contreras; Isabel Varela-Nieto; José García Pichel
Journal:  Transgenic Res       Date:  2014-09-20       Impact factor: 2.788

3.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

4.  IGF-1R contributes to stress-induced hepatocellular damage in experimental cholestasis.

Authors:  Axelle Cadoret; Colette Rey; Dominique Wendum; Khaldoun Elriz; François Tronche; Martin Holzenberger; Chantal Housset
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

Review 5.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).

Authors:  Jamileh Hashemi; Claire Worrall; Daiana Vasilcanu; Mårten Fryknäs; Luqman Sulaiman; Mohsen Karimi; Wen-Hui Weng; Weng-Onn Lui; Christina Rudduck; Magnus Axelson; Helena Jernberg-Wiklund; Leonard Girnita; Olle Larsson; Catharina Larsson
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

7.  Expression of dominant-negative thyroid hormone receptor alpha1 in Leydig and Sertoli cells demonstrates no additional defect compared with expression in Sertoli cells only.

Authors:  Betty Fumel; Pascal Froment; Martin Holzenberger; Gabriel Livera; Philippe Monget; Sophie Fouchécourt
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.